---
title: "Evolv Tech Holdings - CW25 | 8-K: FY2026 Q1 Revenue: USD 46.33 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286150303.md"
datetime: "2026-05-12T20:15:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286150303.md)
  - [en](https://longbridge.com/en/news/286150303.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286150303.md)
generator: "portal-rs"
---

# Evolv Tech Holdings - CW25 | 8-K: FY2026 Q1 Revenue: USD 46.33 M

Revenue: As of FY2026 Q1, the actual value is USD 46.33 M.

EPS: As of FY2026 Q1, the actual value is USD -0.03.

EBIT: As of FY2026 Q1, the actual value is USD -8.025 M.

#### Financial and Operational Metrics (Three Months Ended March 31, 2026, unless otherwise specified)

#### Segment Revenue

-   **Total Revenue**: $46,328 thousand, a 45% increase from $32,007 thousand in Q1 2025.
    -   **Recurring Revenue**: $31,176 thousand, up 21% from $25,753 thousand in Q1 2025.
    -   **Non-recurring Revenue**: $15,152 thousand, up 142% from $6,254 thousand in Q1 2025.
-   **Revenue Breakdown by Type (Q1 2026)**:
    -   Product revenue: $13,421 thousand.
    -   Subscription revenue: $23,148 thousand.
    -   Service revenue: $8,589 thousand.
    -   License fee and other revenue: $1,170 thousand.
-   **Revenue Breakdown by Type (Q1 2025)**:
    -   Product revenue: $2,322 thousand.
    -   Subscription revenue: $19,237 thousand.
    -   Service revenue: $6,730 thousand.
    -   License fee and other revenue: $3,718 thousand.

#### Operational Metrics

-   **Net Loss**: - $5,009 thousand, compared to a net loss of - $1,689 thousand in Q1 2025.
-   **Net Profit Margin**: -10.8%.
-   **Adjusted EBITDA**: $3,944 thousand, compared to $2,064 thousand in Q1 2025.
-   **Adjusted EBITDA Margin**: 8.5%.
-   **Gross Profit (GAAP)**: $23,599 thousand, compared to $19,150 thousand in Q1 2025.
-   **Gross Margin (GAAP)**: 50.9%, compared to 59.8% in Q1 2025.
-   **Adjusted Gross Profit**: $24,075 thousand, compared to $19,472 thousand in Q1 2025.
-   **Adjusted Gross Margin**: 52.0%, compared to 60.8% in Q1 2025.
-   **Total Operating Expenses (GAAP)**: $32,071 thousand, compared to $33,539 thousand in Q1 2025.
    -   Research and development: $5,885 thousand.
    -   Sales and marketing: $12,671 thousand.
    -   General and administrative: $13,515 thousand.
    -   Restructuring costs: $0 thousand in Q1 2026 vs $2,662 thousand in Q1 2025.
-   **Loss from Operations (GAAP)**: - $8,472 thousand, compared to - $14,389 thousand in Q1 2025.
-   **Adjusted Loss from Operations**: - $2,823 thousand, compared to - $3,709 thousand in Q1 2025.

#### Cash Flow

-   **Net Cash Used in Operating Activities**: - $3,179 thousand, compared to - $2,539 thousand in Q1 2025.
-   **Net Cash Provided by (Used in) Investing Activities**: $9,760 thousand, compared to - $9,361 thousand in Q1 2025.
-   **Net Cash Provided by Financing Activities**: $322 thousand, compared to $20 thousand in Q1 2025.
-   **Free Cash Flow**: Not explicitly provided in the reference.

#### Unique Metrics

-   **Ending Annual Recurring Revenue (ARR)**: $127,300 thousand as of March 31, 2026, up 20% from $106,000 thousand as of March 31, 2025.
-   **New Customers**: 48 in Q1 2026, compared to 54 in Q1 2025.
-   **Cash, Cash Equivalents and Marketable Securities**: $61,073 thousand as of March 31, 2026.

#### Outlook / Guidance for 2026

Evolv Technology anticipates total revenues for 2026 to be between $175 million to $180 million, reflecting a year-over-year growth of approximately 20% to 23%. The company expects ending ARR by December 31, 2026, to increase to approximately $145 million to $150 million, representing a 20% to 25% year-over-year growth. Evolv Technology also projects positive full-year Adjusted EBITDA with high single-digit Adjusted EBITDA margins for 2026.

### Related Stocks

- [EVLVW.US](https://longbridge.com/en/quote/EVLVW.US.md)

## Related News & Research

- [Weekly Recap: 1.5M-share inducement grant and furnished Form 8-K PSU award](https://longbridge.com/en/news/298207980.md)
- [Indaptus amends 8-K to update dilution disclosure in ATM prospectus supplement](https://longbridge.com/en/news/298297826.md)
- [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md)
- [REG - General Elec. - Doc re. GE Files 8-K](https://longbridge.com/en/news/298321667.md)
- [REG - Sunbelt Rentals Hldg - Publication of Current Report on Form 8-K](https://longbridge.com/en/news/298451503.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**